Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
Key Financial Performance
R&D expenses $2.4 million for Q3 2025, down from $3.7 million for Q3 2024, a decrease primarily due to reductions in research study and materials expenses, consulting expenses, and payroll and compensation expenses.
General and administrative expenses $1.9 million for Q3 2025, up from $1.5 million in Q3 2024, an increase primarily due to higher business development and investor relations expenditures, professional fees, and patent costs.
Net loss $4.2 million for Q3 2025 ($0.39 per share), compared to $4.5 million ($0.42 per share) in Q3 2024, reflecting a slight improvement in financial performance.
Cash position Approximately $12.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing runway into approximately Q3 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LP-184 Phase Ia clinical trial: Achieved all primary endpoints with a 48% clinical benefit rate in evaluable cancer patients. Observed marked tumor reductions in patients with DNA damage repair mutations.
LP-300 HARMONIC trial: Preliminary Phase II data showed an 86% clinical benefit rate, with one patient achieving a durable complete response for nearly 2 years.
LP-284 program: Generated interest for its novel mechanism of action in non-Hodgkin's lymphoma. Demonstrated complete metabolic response in a heavily pretreated patient.
AI platform RADR: Showcased commercial readiness with modules like PredictBBB and LBx-AI, achieving high prediction accuracy for drug development.
withZeta AI platform: Introduced as a multi-agentic AI system for rare cancer research, integrating vast data sources to accelerate drug development.
Market potential for LP-184: Targeting four high-value indications with a combined annual market potential exceeding $7 billion.
LP-300 market opportunity: Focused on lung cancer in never smokers, representing a global market of approximately $4 billion annually.
LP-284 market opportunity: Targeting non-Hodgkin's lymphoma with a global market potential of $3 billion.
AI tools and services: Estimated to represent several hundred million dollars in stand-alone market potential.
Capital management: Maintained $12.4 million in cash and equivalents as of September 30, 2025, providing runway into Q3 2026.
Strategic changes in Asia: Transitioned CRO services in Taiwan and brought more activities in-house in Japan to reduce costs and improve efficiency.
Scaling AI infrastructure: Established machine learning and data engineering teams in India to expand technical capabilities while maintaining cost efficiency.
Precision medicine approach: Focused on biomarker-driven cancer trials to increase success rates and target specific patient populations.
Commercialization of AI platforms: Positioned RADR and withZeta as revenue-generating assets, enhancing Lantern's role in rare cancer drug development.
Dual engine strategy: Integrated AI capabilities with drug development to transform precision oncology and drug development economics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces challenges in addressing the market opportunity for its drugs, particularly in regions like Asia where the prevalence of certain cancers is higher. Expanding trials into these regions requires strategic partnerships and operational adjustments.
Regulatory Hurdles: The company must navigate complex regulatory pathways, including FDA Fast Track and Orphan Drug Designations, which, while beneficial, require significant resources and compliance efforts.
Supply Chain and Operational Efficiency: Operational changes in Asia, including transitioning CRO services and bringing activities in-house, highlight challenges in maintaining cost efficiency and trial quality.
Economic Uncertainties: The company has a limited cash runway, with funding expected to last only until Q3 2026. Additional funding is critical to sustain operations and achieve strategic objectives.
Strategic Execution Risks: The company’s dual-engine strategy of advancing clinical assets and commercializing AI platforms requires precise execution to avoid resource misallocation and ensure both engines deliver value.
Competitive Pressures: The oncology drug development space is highly competitive, with other companies also pursuing biomarker-driven and AI-supported approaches, which could impact Lantern Pharma’s market share and partnerships.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
LP-184 Phase Ib and Phase II Trials: Lantern Pharma plans to advance LP-184 into multiple targeted Phase Ib and Phase II trials focusing on four high-value indications: triple-negative breast cancer, non-small cell lung cancer with KEAP1 or STK mutations, bladder cancer with DNA repair deficiencies, and first recurrent GBM. These indications represent a combined annual market potential exceeding $7 billion. Each trial will use biomarker-driven enrollment criteria to increase the probability of success.
LP-300 HARMONIC Trial: Lantern Pharma is conducting the LP-300 HARMONIC trial targeting lung cancer in never smokers. The trial has expanded into Japan and Taiwan to access a larger patient population. Preliminary data showed an 86% clinical benefit rate, and a comprehensive data update is planned for December 2025. The global market opportunity for this indication is approximately $4 billion annually.
LP-284 Development: Lantern Pharma is advancing LP-284 for recurrent non-Hodgkin's lymphoma, with a global market opportunity of $3 billion. The company is exploring combination therapy opportunities and expanding into autoimmune diseases like lupus. LP-284 has shown promising preclinical results and has strong intellectual property protection through 2039.
AI Platform Commercialization: Lantern Pharma is commercializing its RADR AI platform, which has demonstrated over 80% prediction success. The platform includes modules like PredictBBB and LBx-AI, which have significant market potential. The company is also launching withZeta, an AI system for rare cancer drug development, aiming to accelerate discovery and reduce costs.
Financial Guidance: Lantern Pharma has $12.4 million in cash and expects this to fund operations into Q3 2026. The company is pursuing additional funding opportunities, including an ATM sales agreement to raise up to $15.53 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status of tracking toward an interim event analysis for the LP-300 trial?
A:At the December webinar, it was noted that they do not expect to reach the 31 events by then, which is positive as it indicates patients are staying on the trial longer. They expect to reach 31 events in early 2026.
Q:What is the update on the Denmark trial?
A:The Denmark trial has been approved, IRBs are set, and a project manager has been assigned. It is expected to start in late December or early January at one investigator-led site in Denmark.
Q:What is the status of the IND submission for the pediatric CNS program?
A:The IND submission is prepared and expected to happen in the next few weeks. Initial patient dosing is anticipated in early 2026, though discussions with sites are ongoing.
Q:What is the update on the withZeta portion of the AI platform?
A:Additional news on withZeta will be shared next week. Early rollout is expected to be interesting and bumpy, with internal use already underway. Select demos will be available in December, with broader rollout in January, February, and Q1.
Q:What is the plan for 184 indications?
A:The plan is to identify the best indications with the biggest impact and move them into larger-scale trials, ideally with partners. Pharma companies have shown interest but want to see early Phase Ib and Phase II data first.
Q:What is Zeta and its purpose?
A:Zeta was developed internally to address rare cancers with no approved therapies. It aims to consolidate scattered data and provide a natural language interface tool for drug development. It will now be a front-facing tool.
Q:What is the trial design for the STAR-001 trial for pediatric brain tumors?
A:The trial design allows for the inclusion of other pediatric high-grade gliomas, including diffuse midline gliomas.
Q:Review of Unclear Management Responses
A:None of the questions appeared to be avoided or lacked clarity in the responses provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Biology
AI tool
ATM
Annual
DNA repair
Dr
FDA Fast
Fast Track
Hodgkin lymphoma
Ia trial
Phase II
Phase Ia
RADR AI
STK
Zeta
cancer drug
cancer trial
carcinoma
cell lymphoma
class
co scientist
database
decrease
grade cell
hypothesis
increase
indication market
interest
lethality
lupus
market opportunity
platform module
reason
reduction
sale
service
success
treatment
trial patient
week
withZeta
LTRN Transcript
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call reveals several negative aspects: increased losses, higher expenses, and unclear management responses regarding key programs and partnerships. Despite some positive developments in clinical trials, the financial health and guidance remain concerning. The expansion into Asia is promising, but supply chain risks and regulatory hurdles pose challenges. The lack of clarity in management's responses during the Q&A further adds to uncertainty, leading to a negative sentiment.
LTRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
